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Pleural infection is a relatively common complication of pneumonia with a broad aetiology. Para-
pneumonic effusions caused by an infection of the pleural membranes occur in 40–57% of cases of
pneumonia. A variable percentage (10–20%) of parapneumonic effusions progresses to empyema (pus)
and/or abscess formation (encapsulation). Pleural infection is associated with signiﬁcant morbidity and
mortality. Diagnosis requires a multidisciplinary approach which may include respiratory physicians,
thoracic surgeons, microbiologists and radiologists. Rigorous and prompt treatment with antibiotics,
good clinical care and timely drainage of effusions remain the cornerstones of effective management.
 2009 Elsevier Ltd. All rights reserved.Educational aims
 To discuss the aetiology and aetiopathogenesis of pleural
infection.
 To point out the relative merits of various forms of treatment in
pleural infection and the evidence base supporting them.
 To emphasize the importance of supportive care in the immu-
nocompromised patient with pleural infection.
 To emphasize the importance of pleural ﬂuid aspiration in the
diagnosis and management of pleural effusions.
 To outline brieﬂy current controversies in the management of
empyema.1. Introduction
Pneumonia (thought to be the chief aetiological process in the
development of pleural space infection) is deﬁned as an infection of
the lung parenchyma with an estimated annual incidence rate of
5–11 cases per 1000 population, with around 50,000 hospital
admissions in the UK per year.1 Parapneumonic effusions caused by
an infection of the pleural membranes occur in 40–57% of cases of
pneumonia. A variable percentage (10–20%) of parapneumonic
effusions progresses to empyema (pus) and/or abscess formation
(encapsulation). Pleural infection is associated with signiﬁcant
morbidity and mortality which may be as high as 20–35% in
immunocompromised patients.2 Mortality in patients who
develop empyema is associated strongly with the presence ofx: þ44 131 242 3878.
fmail.ed.ac.uk (R.L. Riha).
All rights reserved.co-morbidities. Diagnosis requires a multidisciplinary approach
which may include respiratory physicians, thoracic surgeons,
microbiologists and radiologists. Treatment of pleural infection
involves antibiotics, supportive treatment and chest tube drainage
although around 30% of patients fail to respond and require surgical
intervention.32. Aetiology of pleural infection
Risk factors for the development of pleural infection include co-
morbidities such as chronic lung diseases, rheumatoid arthritis,
diabetes and substance abuse including alcoholism.4 Those patients
with a risk of aspiration pneumonia; substance abuse, neuromus-
cular disorders, seizures, mental retardation, GORD and those with
poor dentition are known to have a tendency to develop anaerobic
infections.5 Infections are also more common in the immunocom-
promised, the very young and the elderly. Chest trauma and
iatrogenic causes include surgery and thoracocentesis. For those
patients with hospital acquired infections, the outcome is worse
with an increased length of hospital stay of up to 2 months
compared with community acquired infections which may be up
to 2 weeks.6
Aerobic organisms are most commonly implicated in pleural
infection. Streptococcal species are at the top of the list at around
60% (Streptococcus milleri, pneumoniae, pyogenes and others), fol-
lowed by staphylococcal species (Staphylococcus aureus, MRSA) and
Enterococcus at 15% of total infective causes. The gram-negative
aerobes (Escherichia coli, Klebsiella sp., Proteus sp., Pseudomonas sp.)
cause around 15% of identiﬁed pathogens and anaerobes
(Fusobacterium, Bacteroides, Clostridium, Mycobacterium TB and
Actinomyces) comprise 14%.7 The organism responsible for the
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community acquired empyema, 50% of cases in one series were due
to streptococci and the remainder due to staphylococci, anaerobes
and gram-negative bacilli.8 For hospital acquired empyema (in
association with hospital acquired pneumonia HAP), or iatrogenic
causes, staphylococci, gram-negative bacilli, enterococcus species
and MRSA (in around 20% of cases) are the organisms implicated.
Patients with co-morbidities, especially diabetes or alcoholism,
tend to develop gram-negative empyema. Some pulmonary
parenchymal infections, caused by S. aureus and Klebsiella pneu-
moniae, are more likely to progress to pleural infections than
others.8 Fungi such as Candida and Aspergillus are increasingly
common agents of fungal empyema. A large randomised, multi-
centre trial in pleural infection recently reported that microbio-
logical diagnosis was reached in 57% of cases and an extra 16% were
diagnosed using PCR. Blood cultures from patients were found to be
positive in only 12% of cases but added signiﬁcantly to the data as
often this was the only positive result available.8 In 15–20% of cases,
no identiﬁable microbiological cause was found.
3. Pathogenesis of pleural infection
Pleural infection can be deﬁned as a progressive process,
whereby a self-resolving parapneumonic effusion may progress to
a complex, multi-loculated ﬁbrotic collection which requires
surgical intervention. The pathophysiology of this process evolves
through three distinct phases: the exudative phase, the ﬁbrino-
purulent stage and the organisational stage.9 These stages reﬂect
the changing physiology within the pleural space which may not
always follow a linear fashion and is summarised by Light’s Clas-
siﬁcation (Table 1).10
The exudative phase begins when inﬂammation of the lung
parenchyma causes increased permeability of the pleural
membranes. Transfer of interstitial ﬂuid across the visceral pleura
occurs. Pro-inﬂammatory cytokines (IL-6, 8 and TNF-alpha)
enhance mesothelial permeability and increase vascular perme-
ability, inﬂuenced by immune processes including neutrophil
migration. This results in the formation of increased pleural ﬂuid
volume without bacteria (Table 2). Patients may complain of
pleuritic chest pain which will generally resolve spontaneously
with the correct antibiotic therapy.
The ﬁbrinopurulent phase commences with bacterial invasion
of the pleural space. Normal ﬁbrinolytic activity is disrupted by the
rise in PAI-1 and 2 (plasminogen activator inhibitor) and TNF-alpha
which are directly released from mesothelial cells. Fibrin deposi-
tion results in the formation of ﬁbrinous septae with ﬂuid locula-
tion and adhesions. This process, although part of the healing by
invasion of ﬁbrous tissue, often impairs the efﬁcacy of chest tube
drainage. The physiology of the pleural ﬂuid changes as a result of
bacterial wall-induced neutrophil phagocytic activity causing a rise
in lactic acid and a fall in pH and glucose (Table 2). This stageTable 1
Light’s Classiﬁcation of pleural effusions.
Class Description
Class1 – non-signiﬁcant <10 mm thick on decubitus radiograph
Class 2 – typical
parapneumonic
>10 mm thick, pH> 7.2, glucose> 40 mg/dL.
Class 3 – borderline
complicated
pH 7.0–7.2 or LDH> 1000, gram stainþ culture
negative
Class 4 – simple
complicated
pH< 7.0, gram stain/culture positive, not loculated or
frank pus.
Class 5 – complex
complicated
pH< 7.0, gram stain/culture positive, multiple
loculated.
Class 6 – simple empyema Frank pus, single locule or free ﬂowing.
Class 7 – complex empyema Frank pus, multiple loculations.initiates the point of transition to the infected state. Neutrophils
inﬁltrate the pleural cavity, lactate dehydrogenase is produced and
the ﬂuid becomes frank pus due to bacterial and inﬂammatory cell
lysis and death.
The organising stage is driven by PDGF, with TGF-beta causing
proliferation of ﬁbroblasts which form collagenous, inelastic, ﬁbrous
pleural scaring. This process impairs lung function as re-inﬂation of
the lung is inhibited. At this stage chest tube drainage evenwith the
use of ﬁbrinolytics, will probably fail. Interestingly, the clinical
course varies signiﬁcantly between patients. Some patients do not
develop signiﬁcant pleural scarring; others develop chronic sepsis
and signiﬁcant lung deﬁcits whereas some have spontaneous reso-
lution of the pleural thickening and subsequent recovery.
4. Diagnosis of pleural infections
Clinically, patients with pleural infection present with symp-
toms of pneumonia. Commonly they experience acute onset cough,
often productive of purulent sputum, fever, dyspnoea andmay have
pleuritic chest pain.11 Anaerobic infections may present with non-
speciﬁc features of anorexia, weight loss and malaise. Assessment
of risk factors for suspected pneumonia often helps with diagnosis
in these cases. No clinical features will reliably predict which
patients with effusions will require drainage.12
Chest radiography is the mainstay of diagnostic imaging and can
conﬁrm the presence and size of a pleural effusion and/or consoli-
dation. A pleural based mass or loculated area of ﬂuid may be indic-
ative of the presence of empyema. Pleural aspirate under ultrasound
guidance is particularly useful in the case of small or loculated effu-
sions.ContrastenhancedCTcandifferentiatepulmonaryabscess from
empyema when the ‘‘split pleural sign’’ is present (Fig 1). Pleural
thickening is frequently seen in empyema and its absence may
suggest other pathology.15 MRI gives excellent detail of pleural ﬂuid
characteristics including the presence of septations, but cannot reli-
ably differentiate between malignant and infective effusions.
All patients with pleural effusion in the context of clinical
symptoms suggesting infection should have an aspirate of the ﬂuid
sent for microscopy, biochemistry and culture. If the effusion is
small, the aspirate should be carried out under ultrasound guid-
ance. The presence of frank pus in the aspirate is diagnostic of
empyema.9 A gram-positive stain or positive culture of a non-
purulent aspirate is diagnostic of established pleural infection. In
general, Light’s criteria should be used to differentiate between
an exudate (effusions and empyema) and transudate (other path-
ological process).
In non-purulent ﬂuid, pleural ﬂuid pH is the best indicator of
whether an effusion is likely to be complicated and require
drainage or is simple and likely to resolve spontaneously. Current
guidelines recommend chest drainage in effusions with pH< 7.20
in the correct clinical context, and treatment with antibiotics alone
with pH> 7.20. The effusion can be re-sampled if not responsive to
treatment or the patient is deteriorating.13 Samples for pH testing
should be collected in a heparinised syringe and tested immedi-
ately using a blood gas analyser. If the sample is frank pus then the
pH does not need to be tested, as a chest drain is required for the
treatment of empyema, and the pH gives no useful further clinical
information. Although pH is reliable in predicting the course of an
effusion, acidic pH alone is not diagnostic of pleural infection. Other
causes of pleural effusions may result in acidic effusion (see
Section 5 below) and occasionally infections can cause an alkaline
effusion (Proteus spp.).
Samples of pleural ﬂuid should be sent for microscopy, culture
and sensitivity and are positive in 60% of cases.14 The use of blood
culture bottles for inoculation to test for the presence of anaerobic
organisms is still to be evaluated fully.
Table 2
Pleural ﬂuid stage changes [after Ref. 7].
Observation Simple effusion Complicated effusion Empyema
Appearance Turbid Cloudy Pus
Markers pH> 7.3 pH< 7.2 –
[LDH LDH> 1000 IU/L
Glucose> 60 mg/dL or pleural/serum ratio> 0.5 Glucose< 35 mg/dL
Cell Neutrophils< 10000/mL [ Neutrophils (>10000/mL) –
Gram stain Negative May be positive May be positive
Culture Negative May be positive May be positive
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Pulmonary embolism (PE), bronchial/pleural malignancy,
abdominal/pelvic malignancy, collagen vascular diseases and
iatrogenic causes (drugs) can all mimic pleural space infection.
Patients with malignancy may present with anorexia, weight
loss, fever and raised inﬂammatory markers. Radiology (especially
contrast enhanced CT scan) may be helpful in conﬁrming the
diagnosis; pleural aspirate may clinch the diagnosis (with positive
cytology) or be supportive (e.g. mesothelial cells only with no
inﬂammatory cells). Five percent of rheumatoid arthritis sufferers
have pleural involvement, predominantly males. In rheumatoid
pleuritis the pleural ﬂuid may be acidic, with low glucose levels. In
these cases a history of joint disease and RhF positivity may lead to
the diagnosis.11
Pleural sepsis secondary to oesophageal rupture can be
confused with primary empyema, especially in the elderly or if
there is no clear history of chest pain or vomiting. The pleural
aspirate may show food debris, amylase of salivary origin and
radiology may show hydropneumothorax.24 A chylothorax or
pseudochylous effusion can also lead to clinical confusion and thus,
the aspirate should be analysed for the presence of cholesterol and
triglycerides if there is clinical suspicion of these causes.
Patients with pulmonary embolism may present with fever,
pleuritic chest pain and effusion, but effusion biochemistry will not
be supportive of pleural infection. A CTPA may be required to
eliminate/diagnose the PE, as pleural aspirate ﬁndings are non-
speciﬁc.25Fig. 1. The ‘‘split-pleura’’ sign (presence of contrast enhancement on both the visceral
and parietal pleura, which are therefore clearly visible and separately visible due to the
presence of pleural ﬂuid – hence the name ‘‘split’’). There are also a few septations
within the pleural ﬂuid – an unusual ﬁnding.In pancreatitis, pleural ﬂuid analysis may demonstrate raised
amylase, and isoform analysis may be used to conﬁrm pancreatic
rather than salivary origin.6. Management of pleural infections
Management of pleural infections comprises the general princi-
ples of treatment with antibiotics, attention to nutrition and
supportive measures, with chest drainage or surgical intervention as
necessary. Antibiotic therapy should be instigated as early as possible
and empirical therapy commenced until microbial and biochemical
results are available. Empirical therapywillbe required ina signiﬁcant
numberof cases for thedurationof the illness, aspleuralﬂuidcultures
are negative for microorganisms in around 40%. In community
acquired infections patients should be commenced on a second
generation cephalosporin (cefuroxime) or aminopenicillinwith beta-
lactamase inhibitor (e.g. co-amoxiclav) plus anaerobic therapy
(metronidazole).16 In the penicillin-allergic, ciproﬂoxacin and clin-
damycin may be used. In hospital acquired infections, or those in
whom iatrogenic empyema is likely or where MRSA is a major
problem, a combination of a carbapenem and vancomycinwill cover
likely pathogens.17 Local guidelines and sensitivities of organisms
should be taken into account when determining therapy. Once
investigation results are available, the regimen should be adjusted
accordingly. Consideration should be given to continuing anaerobic
cover, even in the absence of a positive culture, due to the culturing
problems discussed above. Therapy should comprise 1 week of
intravenous antibiotics and then oral formulations for at least 3
weeks. In the event of successful chest drainage, a shorter therapeutic
time may be adequate.18
Insertion of chest drains of a smaller calibre (14 French) is
associated with higher patient satisfaction due to less pain and
mobility problems19; although larger drains continue to be advo-
cated (>20 Fr).20 The drain can be inserted under radiological
guidance which allows insertion into the largest locule if
a complicated pleural effusion is present and reduces the risk of
inadvertent trauma to other organs. The efﬁcacy of ﬁbrinolytic
agents to improve clinical outcomes is not conﬁrmed in large
studies and as such is not recommended as routine practice.21
Further radiological imaging may be required if the effusion fails to
resolve and position of the drain can be checked. Chest drains
remain in place until clinical response dictates removal – they can
be removed when the production of ﬂuid reaches <150 ml/day.22
The indications and timing for surgical intervention have not been
conﬁrmed by good evidence, although patients who have had a few
days of optimal therapy who are not improving should be discussed
with an experienced surgeon.23 First line surgical procedure for these
patients is VATS (video assisted thoracoscopic surgery), although
early evidence showed that 40% of cases will need to be converted to
a formal decortication.24 Excellent recovery results are shown after
decortication in 95% of patients. However, complications can be
signiﬁcant. In some cases, slow withdrawal of drainage therapy over
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ratory failure.
7. Summary
Pleural infection is a relatively common complication of pneu-
moniawith a broad aetiology. The pathogenesis of the infection can
be divided into a number of stages, each of which has a slightly
different treatment algorithm. Investigation and management of
pleural infection are contingent on careful imaging and aspiration
of any effusion present. Rigorous and prompt treatment with
antibiotics, good clinical care and timely drainage of effusions
remain the cornerstones of effective management. Many of the
processes accepted as dogma in the care of pleural infection are
based on empiricism and there remains much scope for research in
this important cause of morbidity in the population.
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Educational questions
Answer the following questions:
1. Which are the most commonly implicated organisms in pleural
infection in the community?
a. Streptococci
b. Staphylococci
c. Pseudomonas spp.
d. Fusobacterium spp.
e. Mycobacteria
2. According to current treatment guidelines, pleural effusions
should be drained if the pH is:
a. >7.20
b. >7.50
c. <7.20
d. >7.40
3. All of the following can cause pleural effusions EXCEPT:
a. Pulmonary embolism
b. Heart failure
c. Rheumatoid arthritis
d. Osteoarthritis
e. Abdominal malignancy with ascites
4. Pleural ﬂuid cultures are negative for microorganisms in what
number of cases?
a. 30%
b. 70%c. 90%
d. 40%
e. 10%
5. In community acquired pleural infections, patients should be
commenced on which of the following antibiotics initially?
a. Ciproﬂoxacin alone
b. Vancomycin alone
c. Ticarcillin and tobramycin
d. Meropenem and metronidazole
e. A second generation cephalosporin and metronidazoleReferences
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